KD-414
/ Meiji Seika
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 04, 2024
Safety and Immunogenicity of Booster Vaccination Against COVID-19 with Whole-SARS-CoV-2-Virion Inactivated Vaccine KD-414: A Phase 1 Trial in Japan
(IDWeek 2024)
- No abstract available
Clinical • P1 data • Infectious Disease • Novel Coronavirus Disease
1 to 1
Of
1
Go to page
1